Applying methylation haplotype analysis to cell-free DNA
DNA methylation has once been called the '5th DNA base' due to its importance in gene regulation, and has been studied for decades. With the advent of next-generation sequencing (NGS) methylation has been studied on a genome-wide level, an expensive process requiring both generating sequence data and analyzing sequence data many orders of magnitude higher than what a typical clinical laboratory can handle.
Targeted methylation approaches have historically not been developed due to technical hurdles. Singlera announces a unique approach, examining methylation haplotypes (adjacent methylation sites on the same contiguous strand of DNA) from cell-free DNA as a method for cancer biomarker detection.
By using a highly specific and targeted methylation enrichment method, both the overall sample input requirement is lowered and the overall amount of sequencing necessary for excellent sensitivity is reduced.
Empirical Classifier – Derived from over 20,000 methylation haplotypes and 10 years of volunteer samples
High Sensitivity and Specificity – Pilot study results show greater than 97% sensitivity and over 99% specificity *
Early Detection of Cancer – Data suggests detection of cancer four years before earliest conventional diagnosis
Efficient biomarker screening technology coupled with fast custom targeted methylation haplotyping and proprietary bioinformatics analysis.
Take a closer look at our leading-edge research in methylation and its role in disease in top research publications.
Learn how Singlera’s methylation haplotyping technology can give better cancer biomarker sensitivity.
Collaboration and Co-Development
Do you see promise in our methylation haplotype approach? Do you think it could complement work you are doing in developing in-vitro diagnostics for cancer?
Research Study Results
Sensitivity of PanSeer 4 years pre-conventional diagnosis
Specificity of PanSeer across 498 healthy individuals
Sensitivity of ColonES in Stage I Colorectal cancer
Specificity of ColonES in healthy individuals
The Co-Founders of Singlera Genomics
Discover The Future
At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future.